Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LY2275796||ISIS 183750||LY2275796 is an antisense oligonucleotide targeted against eukaryotic initiation factor 4E (eIF-4E), which results in decreased eIF-4E expression and potentially leads to reduced growth of eIF-4E-expressing tumors (PMID: 17786246, PMID: 21831956, PMID: 27194579).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||no benefit||LY2275796||Phase I||Actionable||In a Phase I study, treatment with LY2275796 demonstrated safety and resulted in reduced eIF-4E expression, but did not demonstrate antitumor effects in patients with advanced solid tumors (PMID: 21831956).||21831956|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|